# US Angioplasty Balloons Market

> US Angioplasty Balloons Market Research Report: Size, Share, Trend Analysis By Types (Drug-Eluting Balloons, Plain Old Balloons, Scoring Balloons), By Applications (Coronary Angioplasty, Peripheral Angioplasty, Renal Angioplasty), By Material (Polymer, Latex, Metal) and By End Use (Hospitals, Ambulatory Surgical Centers, Cardiac Catheterization Laboratories) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 3.94%
- **2024:** $ 850 Million
- **2025:** $ 883.49 Million
- **2035:** $ 1,300 Million
- **Key Players:** Boston Scientific (US), Medtronic (US), Abbott Laboratories (US), B. Braun Melsungen AG (DE), Terumo Corporation (JP), Cordis Corporation (US), Cook Medical (US), AngioDynamics (US), Asahi Intecc Co., Ltd. (JP)

**Report ID:** MRFR/HC/18033-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-angioplasty-balloons-market-19580

---

## Market Summary

## **US Angioplasty Balloons Market Overview**

As per MRFR analysis, the US Angioplasty Balloons Market Size was estimated at 398.44 (USD Million) in 2023. The US Angioplasty Balloons Market Industry is expected to grow from 450(USD Million) in 2024 to 750 (USD Million) by 2035. The US Angioplasty Balloons Market CAGR (growth rate) is expected to be around 4.753% during the forecast period (2025 - 2035).

### **Key US Angioplasty Balloons Market Trends Highlighted**

The US Angioplasty Balloons Market has been experiencing notable trends driven by an increasing prevalence of cardiovascular diseases. An aging population coupled with lifestyle factors such as obesity and diabetes has significantly raised the demand for angioplasty procedures. Furthermore, there is a growing emphasis on minimally invasive surgeries, leading to an increased adoption of angioplasty balloons due to their effectiveness in treating narrowed arteries with reduced recovery time for patients.

Advancements in technology are also shaping the market, with innovations such as drug-eluting balloons and bioresorbable materials gaining traction. These developments enhance treatment outcomes and reduce the risk of restenosis. The rise of telemedicine and remote patient monitoring systems has bolstered patient awareness and compliance, encouraging more individuals to seek treatments for cardiovascular issues and subsequently driving the market.

Opportunities for growth in the US Angioplasty Balloons Market can be captured through enhanced collaborations between manufacturers and healthcare providers for clinical trials, improving product effectiveness and patient outcomes. Additionally, increasing investments in research and development present a pathway for companies to innovate and offer advanced product solutions.

Recent times have shown increasing regulatory support for advanced angioplasty devices, promoting innovation while ensuring patient safety. This regulatory clarity encourages new entrants in the market, fostering a competitive environment that can lead to better products and services. Overall, the combination of a rising patient base, technological advancements, and supportive regulatory frameworks presents a dynamic landscape for the US Angioplasty Balloons Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **US Angioplasty Balloons Market Drivers**

#### **Rising Incidence of Cardiovascular Diseases**

The US [Angioplasty Balloons Market](../../../reports/angioplasty-balloons-market-9614) Industry is significantly driven by the increasing prevalence of cardiovascular diseases (CVDs), which remain among the leading causes of death in the United States. According to the Centers for Disease Control and Prevention (CDC), nearly 697,000 people died from heart disease in 2020, accounting for 1 in every 5 deaths.

This alarming statistic highlights a growing patient population that necessitates effective treatment options, including angioplasty balloons. Moreover, advancements in diagnostic technologies and an increase in screening practices have led to earlier detection of heart diseases, thereby amplifying the demand for angioplasty procedures. The American Heart Association (AHA) reports that the number of coronary angioplasty procedures performed annually has been steadily increasing, thereby propelling the US Angioplasty Balloons Market forward. The convergence of these factors suggests a robust future growth trajectory for the industry.

#### **Technological Innovations in Angioplasty Balloons**

Technological advancements in the design and manufacturing of angioplasty balloons are a crucial driver for the US Angioplasty Balloons Market Industry. Newer technologies such as drug-coated balloons (DCBs) and bioabsorbable balloons have emerged, offering enhanced efficacy and reduced complications during procedures.

As reported by the Food and Drug Administration (FDA), drug-coated balloons have shown to significantly decrease the rate of restenosis in patients, a common concern that leads to repeated interventions. The introduction of these innovative products has also attracted key players in the market who are investing heavily in Research and Development (R&D) to stay ahead of the competition. For example, established organizations like Boston Scientific and Medtronic have made considerable advancements in balloon technology, contributing to the overall growth of the angioplasty market in the US.

#### **Increase in Awareness and Preventive Healthcare**

Heightened awareness about heart health and preventive healthcare measures plays a pivotal role in driving the US Angioplasty Balloons Market Industry. Initiatives led by organizations such as the CDC and AHA aim to educate the American public on the risks associated with cardiovascular diseases and the importance of early intervention.

As a result, there has been a marked increase in the number of people seeking preventive check-ups and adopting heart-healthy lifestyles. This growing trend is supported by recent surveys that indicate over 60% of adults are now aware of their cholesterol levels and cardiovascular risk factors. As more individuals undergo routine screenings, early signs of cardiovascular issues are identified, leading to an increased incidence of angioplasty procedures and subsequently driving market growth.

#### **Government Policies and Reimbursement Framework**

Supportive government policies and favorable reimbursement frameworks are essential in augmenting the US Angioplasty Balloons Market Industry. Various healthcare reforms aim to enhance access to preventive services and treatment options for cardiovascular diseases. According to healthcare policy analysts, there has been an improvement in federal and state-level reimbursements for angioplasty procedures, making them more accessible to patients.

This is particularly evident in Medicare and Medicaid programs, which have recognized the importance of angioplasty in treating coronary artery disease. The result is a more robust healthcare environment that supports healthcare providers and patients alike, leading to increased usage of angioplasty balloons in the US market.

## **US Angioplasty Balloons Market Segment Insights**

### **Angioplasty Balloons Market Type Insights**

The US Angioplasty Balloons Market has seen significant evolution in recent years, particularly in the Type segment which includes Drug-Eluting Balloons, Plain Old Balloons, and Scoring Balloons. The Drug-Eluting Balloons segment is particularly noteworthy as it combines the mechanical action of balloon dilation with localized drug delivery. This has led to improved outcomes in patients with complex lesions, and its adoption has been growing steadily due to advancements in drug formulations and balloon technologies. It plays a crucial role in reducing the rates of restenosis, making it a vital tool in the treatment of coronary artery diseases.

On the other hand, Plain Old Balloons have maintained a strong presence in the market for their simplicity and efficacy in specific conditions. They are cost-effective and often used in various clinical settings, contributing to their popularity among healthcare providers. The Scoring Balloons segment stands out due to its unique design features, which allow for enhanced plaque modification and improved vessel wall expansion. This technology is particularly beneficial for patients with fibrous plaques whom traditional balloons may struggle to treat effectively.

Overall, the segmentation within the US Angioplasty Balloons Market highlights the diverse approaches to angioplasty interventions, catering to different clinical needs and embracing innovation to enhance patient outcomes. As each sub-segment continues to develop, a keen focus on clinical efficacy and safety will likely guide future market dynamics.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Angioplasty Balloons Market Application Insights**

The US Angioplasty Balloons Market is characterized by its diverse Applications, prominently featuring Coronary Angioplasty, Peripheral Angioplasty, and Renal Angioplasty. Coronary Angioplasty is crucial as it addresses blockages in coronary arteries and plays a significant role in managing cardiovascular diseases, a leading health concern in the United States.

Peripheral Angioplasty focuses on enhancing blood flow in peripheral arteries, which is vital for patients suffering from peripheral artery disease, an issue that affects millions in the US. Lastly, Renal Angioplasty is essential for individuals with renal artery stenosis, a condition that can lead to hypertension and other complications. Market growth in these segments is propelled by the increasing prevalence of cardiovascular conditions and advancements in balloon technology that improve patient outcomes. However, challenges such as high treatment costs and complications associated with procedures persist.

Overall, the emphasis on minimally invasive techniques and the growing acceptance of angioplasty procedures present significant opportunities for further development within these Applications in the US Angioplasty Balloons Market.

### **Angioplasty Balloons Market Material Insights**

The US Angioplasty Balloons Market, particularly focusing on the Material segment, showcases significant diversity and innovation. This segment includes various materials such as Polymer, Latex, and Metal, each playing a crucial role in the functionality of angioplasty balloons. Polymers are gaining traction in the market due to their flexibility and biocompatibility, making them favorable for both patients and healthcare providers.

Latex, while historically used, is seeing a decline in preference due to allergy concerns, so manufacturers are now leaning toward alternatives that ensure patient safety. Metal balloons are particularly valued for their strength and durability, providing reliable performance in high-pressure situations during procedures. With an increasing number of cardiovascular interventions in the US, driven by rising incidences of heart diseases, the demand for these materials is expected to grow significantly. The focus on Research and Development is leading to advancements in material technology, enabling enhancements in balloon design and effectiveness, thereby influencing the overall US Angioplasty Balloons Market statistics.

### **Angioplasty Balloons Market End Use Insights**

The US Angioplasty Balloons Market, particularly focusing on the End Use segment, is showcasing diverse applications across various healthcare settings, driving significant market growth. Hospitals play a critical role in this segment as they are equipped with advanced facilities and technologies, allowing for complex angioplasty procedures and offering comprehensive post-operative care.

Ambulatory Surgical Centers are increasingly popular for less invasive procedures due to their efficiency and lower costs, providing an attractive alternative for patients requiring angioplasty. Additionally, Cardiac Catheterization Laboratories are pivotal within this market, as they facilitate specialized cardiac interventions, enhancing patient outcomes and procedural safety. This growing focus on cardiac health in the US, influenced by increasing rates of cardiovascular diseases, further underscores the importance of these facilities in the angioplasty process.

The market dynamics reflect a broader trend towards outpatient care and rapid advancements in minimally invasive techniques, which are transforming patient management strategies and making these end-use settings vital in improving healthcare delivery in the United States.

## **US Angioplasty Balloons Market Key Players and Competitive Insights**

The US Angioplasty Balloons Market is characterized by intense competition among various players striving to innovate and expand their market presence. This market involves significant technological advancements, including the development of specialized balloon catheters designed for various vascular interventions. With the increasing prevalence of cardiovascular diseases and the aging population, the demand for angioplasty procedures has risen sharply, leading to a flourishing market environment. Players are deploying strategies such as product differentiation, extensive research and development, and strategic partnerships to gain a competitive edge. Additionally, regulatory approvals and compliance with strict industry standards are crucial factors influencing market dynamics.

As a result, understanding competitive insights within this sector is vital for stakeholders looking to navigate the landscape effectively.

Medline Industries holds a prominent position in the US Angioplasty Balloons Market, showcasing unique strengths through its robust product offerings and extensive distribution network. Known for delivering high-quality medical supplies, the company emphasizes efficiency and reliability in its angioplasty balloon products. Medline Industries leverages its established relationships with healthcare providers, hospitals, and specialty clinics, ensuring widespread accessibility and availability of its products within the United States. The company's commitment to customer service and education further enhances its competitive stance, allowing healthcare professionals to leverage best practices for optimal patient outcomes.

Additionally, with a diverse portfolio that includes various medical products, Medline Industries remains adaptable to market changes and demands.

The Spectranetics Corporation features prominently in the US Angioplasty Balloons Market, focusing on innovative solutions within the realm of vascular intervention. The company is recognized for its advanced drug-coated balloon technology aimed at treating coronary and peripheral artery diseases. Key products include balloon catheters that provide targeted therapy, improving patient outcomes while minimizing complications. The Spectranetics Corporation is actively engaged in collaborations and partnerships to further enhance its product offerings, which bolsters its market presence. Strengths include a strong research and development focus and a commitment to delivering safe, effective medical devices.

In recent years, the company has participated in strategic mergers and acquisitions that have strengthened its position and expanded its market reach, providing an edge in a competitive landscape.

### **Key Companies in the US Angioplasty Balloons Market Include**

### **US Angioplasty Balloons Market Industry Developments**

Recent developments in the US Angioplasty Balloons Market indicate a significant focus on technological advancements and product enhancements aimed at improving patient outcomes. Companies such as Medtronic, Boston Scientific, and Abbott are actively engaging in innovation cycles, introducing new balloon designs that enhance deliverability and performance during procedures.

The ongoing trend of hospital acquisitions and partnerships has also contributed to market dynamics, with Cardinal Health acquiring specific assets from other medical device companies to expand its cardiovascular portfolio, particularly in July 2023. Notably, Medline Industries and C. R. Bard have reported increased market valuation due to rising demand for minimally invasive procedures, resulting from advancements in interventional cardiology.

Furthermore, in September 2023, it was announced that Terumo agreed to acquire certain components of the Spectranetics Corporation, strengthening its position in the angioplasty balloon sector. The US market is witnessing a surge in investments from both established players and startups, with a growing emphasis on Research and Development to address the challenges in treating cardiovascular diseases. The continued focus on regulatory approvals and clinical outcomes remains a priority within the industry, shaping the future landscape of the angioplasty balloon market in the US.

## **US Angioplasty Balloons Market Segmentation Insights**

### **Angioplasty Balloons Market Type Outlook**

### **Angioplasty Balloons Market Application Outlook**

### **Angioplasty Balloons Market Material Outlook**

### **Angioplasty Balloons Market End Use Outlook**

## Market Drivers

### Increased Healthcare Expenditure

The rising healthcare expenditure in the US is a significant driver for the angioplasty balloons market. With healthcare spending projected to reach $6.2 trillion by 2028, there is a growing emphasis on investing in advanced medical technologies. This increase in funding allows for the procurement of innovative angioplasty balloons, which are crucial for effective cardiovascular interventions. As hospitals and healthcare facilities allocate more resources towards improving patient care, the angioplasty balloons market is likely to benefit from enhanced access to state-of-the-art devices. Furthermore, the focus on value-based care may encourage the adoption of angioplasty procedures, further propelling market growth. The financial commitment to healthcare advancements indicates a promising outlook for the angioplasty balloons market.

### Growing Awareness of Preventive Healthcare

The growing awareness of preventive healthcare among the US population is driving the angioplasty balloons market. As individuals become more informed about cardiovascular health, there is an increasing demand for early intervention strategies. This shift in mindset encourages patients to seek medical advice and undergo procedures such as angioplasty at earlier stages of disease progression. Consequently, healthcare providers are more likely to recommend angioplasty balloons as a viable treatment option. The emphasis on preventive care aligns with national health initiatives aimed at reducing the burden of cardiovascular diseases. This trend suggests a potential increase in the volume of angioplasty procedures, thereby positively impacting the angioplasty balloons market.

### Regulatory Support for Medical Innovations

Regulatory support for medical innovations is a crucial driver for the angioplasty balloons market. The US Food and Drug Administration (FDA) has implemented streamlined processes for the approval of new medical devices, including angioplasty balloons. This regulatory environment fosters innovation and encourages manufacturers to develop advanced products that meet the evolving needs of healthcare providers. As a result, the angioplasty balloons market is likely to experience an influx of new technologies that enhance treatment efficacy and patient safety. The proactive stance of regulatory bodies in facilitating the introduction of innovative devices may lead to increased competition and improved product offerings in the market. This supportive framework is essential for the continued growth and evolution of the angioplasty balloons market.

### Rising Prevalence of Cardiovascular Diseases

The increasing incidence of cardiovascular diseases in the US is a primary driver for the angioplasty balloons market. According to the American Heart Association, cardiovascular diseases account for approximately 697,000 deaths annually, highlighting a critical health concern. This alarming statistic suggests a growing demand for effective treatment options, including angioplasty procedures. As healthcare providers seek to address this rising burden, the utilization of angioplasty balloons becomes essential. The market is projected to witness substantial growth, with estimates indicating a CAGR of around 6.5% over the next few years. This trend underscores the necessity for innovative solutions in the angioplasty balloons market, as healthcare systems strive to improve patient outcomes and reduce mortality rates associated with cardiovascular conditions.

### Technological Innovations in Medical Devices

Technological advancements in medical devices are significantly influencing the angioplasty balloons market. Innovations such as drug-eluting balloons and bioresorbable materials are enhancing the efficacy of angioplasty procedures. These advancements not only improve patient outcomes but also reduce the risk of restenosis, a common complication following angioplasty. The market for angioplasty balloons is expected to expand as healthcare providers increasingly adopt these cutting-edge technologies. In 2025, the market is anticipated to reach approximately $2.5 billion, driven by the demand for more effective and safer treatment options. As the industry continues to evolve, the integration of advanced technologies will likely play a pivotal role in shaping the future of the angioplasty balloons market.

## Future Outlook

The [Angioplasty Balloons Market](https://www.marketresearchfuture.com/reports/angioplasty-balloons-market-9614) is projected to grow at a 3.94% CAGR from 2025 to 2035, driven by technological advancements, increasing cardiovascular diseases, and rising healthcare expenditures.

**New opportunities:**

- Development of biodegradable angioplasty balloons for enhanced patient safety. Expansion into telehealth platforms for remote monitoring of angioplasty procedures. Partnerships with hospitals for exclusive supply agreements on innovative balloon technologies.

By 2035, the angioplasty balloons market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Drug-Eluting Balloons (Largest) vs. Scoring Balloons (Fastest-Growing)

In the US angioplasty balloons market, Drug-Eluting Balloons dominate the segment, holding a significant share due to their effectiveness in preventing restenosis. Plain Old Balloons, while still relevant, are trailing in market share as more clinicians prefer innovative options that provide sustained therapeutic benefits. Scoring Balloons have been steadily gaining traction, appealing to a niche market looking for precision in severe lesion cases.

Growth in this segment is primarily driven by technological advancements, increasing prevalence of cardiovascular disorders, and an aging population. Additionally, the growing preference for minimally invasive procedures among healthcare professionals fuels the demand for Drug-Eluting and Scoring Balloons. Emerging research and development initiatives are expected to enhance product offerings, thereby promoting further market growth.

Balloons: Drug-Eluting (Dominant) vs. Scoring (Emerging)

Drug-Eluting Balloons are characterized by their ability to release medication directly to the artery lining, significantly reducing the chances of restenosis and enhancing patient outcomes. They have established a strong market presence due to their clinical efficacy, making them the choice of many healthcare providers. On the other hand, Scoring Balloons present an emerging option designed to facilitate successful dilatation in calcified lesions through carefully engineered scoring elements that create microfractures. While currently less dominant, their innovative approach appeals to a growing number of procedures, marking them as a promising segment in the evolving landscape of the US angioplasty balloons market.

### By Application: Coronary Angioplasty (Largest) vs. Peripheral Angioplasty (Fastest-Growing)

In the US angioplasty balloons market, the distribution among application segments indicates that coronary angioplasty holds the largest market share, significantly outpacing peripheral and renal angioplasty. This segment is primarily driven by the high prevalence of coronary artery diseases and the growing aging population. Conversely, while peripheral angioplasty comprises a smaller market share, it is witnessing rapid growth due to increased awareness of peripheral arterial diseases and advancements in technology.

Growth trends in the US angioplasty balloons market are heavily influenced by rising healthcare expenditure and an emphasis on minimally invasive procedures. The coronary angioplasty segment remains dominant, yet the peripheral segment exhibits a promising growth trajectory, attributed to innovative product developments and increasing investment in healthcare infrastructure. Furthermore, renal angioplasty is emerging gradually, as healthcare providers focus on comprehensive cardiovascular care and improving patient outcomes.

Coronary Angioplasty (Dominant) vs. Peripheral Angioplasty (Emerging)

Coronary angioplasty is characterized as the dominant segment in the US angioplasty balloons market, primarily due to its established clinical applications and strong physician preference for balloon angioplasty in treating coronary artery diseases. The segment benefits from long-term procedural success and a proven track record, making it the go-to choice for both patients and clinicians. On the other hand, peripheral angioplasty is emerging actively, gaining traction as clinical guidelines expand and more cases of peripheral artery disease are diagnosed. This segment is increasingly recognized for its role in enhancing blood flow and relieving symptoms in peripheral vascular conditions, supported by technological advancements that improve treatment efficacy.

### By Material: Polymer (Largest) vs. Latex (Fastest-Growing)

In the US angioplasty balloons market, the material segment is primarily dominated by Polymer balloons, which have a substantial market share due to their durability and flexibility, making them suitable for a variety of clinical applications. Latex, although smaller in share, is gaining traction with its cost-effectiveness and unique properties, appealing to a segment of users focused on budget considerations while ensuring adequate performance.

As the market evolves, the growth of Latex balloons is attributed to rising healthcare expenditures and a shift towards minimally invasive procedures, which favor the adoption of various types of balloons. Furthermore, advancements in Polymer technology are promoting the longevity and efficiency of these products, thus maintaining their market leadership. The demand for innovation in balloon materials also indicates potential for emerging segments, enhancing the competitive landscape.

Material: Polymer (Dominant) vs. Latex (Emerging)

Polymer balloons have established themselves as the dominant choice in the market, known for their superior performance, resilience, and compatibility with various angioplasty techniques. Their manufacturing process has advanced to include coatings that enhance drug delivery and minimize thrombosis risk. On the other hand, Latex balloons are emerging as a viable option, particularly for cost-conscious facilities. They are often perceived as less robust than their Polymer counterparts but are effective for specific applications where flexibility and soft tissue accommodation are critical. As continuous research unfolds, these materials are anticipated to adapt and evolve, further segmenting their uses in clinical practice.

### By End Use: Hospitals (Largest) vs. Cardiac Catheterization Laboratories (Fastest-Growing)

In the US angioplasty balloons market, hospitals account for the largest share of the segment. This dominance is primarily due to the high volume of procedures conducted in these facilities, where the need for advanced and reliable balloon technologies is critical to delivering effective patient care. Ambulatory surgical centers, while significant, capture a smaller portion of the overall market as they are often focused on less complex cases. The landscape of these end-use facilities highlights the need for tailored products to meet varying patient needs.

However, the growth trend for the angioplasty balloons segment is robust, with cardiac catheterization laboratories emerging as the fastest-growing end-use segment. Factors driving this growth include technological advancements in balloon designs and the increasing adoption of minimally invasive procedures. Enhanced procedural efficiency and better patient outcomes are pivotal in shifting healthcare providers' preference toward cardiac catheterization laboratories. This shift indicates a promising future in the demand for specialized angioplasty balloons in these settings.

Hospitals: Dominant vs. Cardiac Catheterization Laboratories: Emerging

Hospitals play a dominant role in the US angioplasty balloons market due to their comprehensive care capabilities and the large number of cardiac interventions performed. This segment benefits from advanced infrastructure, specialized staff, and the ability to handle complex cases. In contrast, cardiac catheterization laboratories are emerging as a significant segment driven by technological innovation and increasing acceptance of catheter-based procedures. These facilities specialize in cardiovascular diagnostics and interventions, providing targeted care that aligns with patient-centered healthcare trends. The rising preference for outpatient procedures is likely to bolster the growth of cardiac catheterization laboratories, complementing the longstanding dominance of hospitals in angioplasty procedures.

## Competitive Benchmarking

The angioplasty balloons market exhibits a dynamic competitive landscape characterized by rapid innovation and strategic maneuvering among key players. Major companies such as Boston Scientific (US), Medtronic (US), and Abbott Laboratories (US) are at the forefront, leveraging their extensive research and development capabilities to enhance product offerings. Boston Scientific (US) focuses on expanding its product portfolio through innovative technologies, while Medtronic (US) emphasizes strategic partnerships to bolster its market presence. Abbott Laboratories (US) appears to prioritize digital transformation initiatives, aiming to streamline operations and improve patient outcomes. Collectively, these strategies contribute to a competitive environment that is increasingly driven by technological advancements and patient-centric solutions. Key business tactics within the angioplasty balloons market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure is moderately fragmented, with several players vying for market share. The collective influence of these key players shapes the competitive dynamics, as they engage in continuous innovation and strategic collaborations to maintain their positions. In October 2025, Boston Scientific (US) announced the launch of a next-generation drug-coated balloon designed to improve outcomes in patients with coronary artery disease. This strategic move underscores the company's commitment to innovation and its focus on addressing unmet clinical needs. By introducing advanced technologies, Boston Scientific (US) aims to solidify its leadership position in the market and enhance patient care. In September 2025, Medtronic (US) entered into a partnership with a leading telehealth provider to integrate remote monitoring capabilities into its angioplasty balloon systems. This collaboration is strategically significant as it aligns with the growing trend of digital health solutions, enabling healthcare providers to monitor patient progress more effectively and improve treatment outcomes. Such initiatives reflect Medtronic's (US) focus on enhancing the overall patient experience through technology. In August 2025, Abbott Laboratories (US) expanded its manufacturing capabilities in the US to meet the increasing demand for angioplasty balloons. This expansion is indicative of the company's proactive approach to scaling operations and ensuring supply chain reliability. By enhancing its production capacity, Abbott Laboratories (US) positions itself to respond swiftly to market demands and maintain a competitive edge. As of November 2025, current competitive trends in the angioplasty balloons market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into product development. Strategic alliances are shaping the landscape, as companies collaborate to leverage complementary strengths and enhance innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative solutions, and robust supply chain management. This shift suggests that companies that prioritize innovation and reliability will be better positioned to thrive in the evolving market.

## Recent News & Developments

Recent developments in the US Angioplasty Balloons Market indicate a significant focus on technological advancements and product enhancements aimed at improving patient outcomes. Companies such as Medtronic, Boston Scientific, and Abbott are actively engaging in innovation cycles, introducing new balloon designs that enhance deliverability and performance during procedures.

The ongoing trend of hospital acquisitions and partnerships has also contributed to market dynamics, with Cardinal Health acquiring specific assets from other medical device companies to expand its cardiovascular portfolio, particularly in July 2023. Notably, Medline Industries and C. R. Bard have reported increased market valuation due to rising demand for minimally invasive procedures, resulting from advancements in interventional cardiology.

Furthermore, in September 2023, it was announced that Terumo agreed to acquire certain components of the Spectranetics Corporation, strengthening its position in the angioplasty balloon sector. The US market is witnessing a surge in investments from both established players and startups, with a growing emphasis on Research and Development to address the challenges in treating cardiovascular diseases. The continued focus on regulatory approvals and clinical outcomes remains a priority within the industry, shaping the future landscape of the angioplasty balloon market in the US.

## Report Scope

| MARKET SIZE 2024 | 850.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 883.49(USD Million) |
| MARKET SIZE 2035 | 1300.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.94% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Boston Scientific (US), Medtronic (US), Abbott Laboratories (US), B. Braun Melsungen AG (DE), Terumo Corporation (JP), Cordis Corporation (US), Cook Medical (US), AngioDynamics (US), Asahi Intecc Co., Ltd. (JP) |
| Segments Covered | Type, Application, Material, End Use |
| Key Market Opportunities | Advancements in biodegradable materials enhance safety and efficacy in the angioplasty balloons market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the angioplasty balloons market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US angioplasty balloons market in 2024?**
A: The overall market valuation was $850.0 Million in 2024.

**Q: What is the projected market valuation for the US angioplasty balloons market by 2035?**
A: The projected valuation for 2035 is $1300.0 Million.

**Q: What is the expected CAGR for the US angioplasty balloons market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 3.94%.

**Q: Which type of angioplasty balloon had the highest valuation in 2024?**
A: In 2024, Plain Old Balloons had the highest valuation at $350.0 Million.

**Q: What are the projected valuations for Drug-Eluting Balloons and Scoring Balloons by 2035?**
A: By 2035, Drug-Eluting Balloons are projected to reach $550.0 Million, while Scoring Balloons may reach $250.0 Million.

**Q: Which application segment is expected to have the highest growth in the US angioplasty balloons market?**
A: Peripheral Angioplasty is expected to have the highest growth, with a projected valuation of $600.0 Million by 2035.

**Q: What material segment is projected to show significant growth by 2035?**
A: The Polymer material segment is projected to show significant growth, reaching $480.0 Million by 2035.

**Q: Which end-use segment had the highest valuation in 2024?**
A: In 2024, the Hospitals end-use segment had the highest valuation at $340.0 Million.

**Q: What is the projected valuation for Ambulatory Surgical Centers by 2035?**
A: The projected valuation for Ambulatory Surgical Centers by 2035 is $390.0 Million.

**Q: Who are the key players in the US angioplasty balloons market?**
A: Key players include Boston Scientific, Medtronic, Abbott Laboratories, and Cordis Corporation.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-angioplasty-balloons-market-19580*